Treatment of platinum-resistant ovarian cancer.
In the United States, almost 70% of the 23,000 women diagnosed annually with epithelial ovarian cancer present with advanced disease (FIGO stages III-IV). Primary therapy for these patients includes surgical cytoreduction and 6-8 courses of platinum- and taxane-based chemotherapy. Although 90% of patients will respond to this multi-modality combination regimen, most patients will experience recurrences. The 5 year survival for women with stage III disease is 15-30% and 0-20% for those with stage IV disease. Medical and gynecological oncologists, therefore, must be prepared to treat many women with recurrent ovarian cancer.
Trimble
E L
EL
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA. tt6m@nih.gov
Wright
J
J
Christian
M C
MC
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods; D019008:Drug Resistance, Neoplasm; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000523:psychology; D010984:Platinum / Q000627:therapeutic use*; D011788:Quality of Life / Q000523:psychology
D000970:Antineoplastic Agents; D010984:Platinum